BRISTOL MYERS SQUIBB CO

BMY 10-K · FY 2025
API behind this page

BMY FY 2025 request

Playground key active
Request URL /api/financials?ticker=BMY&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue (FY) — — —
Show Product Lines breakouts
Abecma 427 406 +5.2%
Abraxane 368 875 -57.9%
Alliance and other revenues 1,438 1,522 -5.5%
Alliance revenues 447 479 -6.7%
Alliance revenues · Collaborative Arrangement 447 479 -6.7%
Breyanzi 1,358 747 +81.8%
Camzyos 1,068 602 +77.4%
Cobenfy 155 10 +1450.0%
Eliquis 14,443 13,333 +8.3%
Gross product sales 88,085 83,671 +5.3%
Growth Portfolio 26,409 22,563 +17.0%
Krazati 205 126 +62.7%
Legacy Portfolio 21,785 25,737 -15.4%
Net product sales 46,756 46,778 -0.0%
Net product sales · Collaborative Arrangement 14,588 13,587 +7.4%
Net product sales · Ono 178 158 +12.7%
Net product sales · Pfizer 14,328 13,187 +8.7%
Opdivo 10,049 9,304 +8.0%
Opdivo Qvantig 238 — —
Opdualag 1,185 928 +27.7%
Orencia 3,705 3,682 +0.6%
Other Growth products 1,924 1,643 +17.1%
Other Legacy products 798 925 -13.7%
Other revenues 992 1,043 -4.9%
Pomalyst/Imnovid 2,733 3,545 -22.9%
Reblozyl 2,327 1,773 +31.2%
Revlimid 2,951 5,773 -48.9%
Sotyktu 291 246 +18.3%
Sprycel 493 1,286 -61.7%
Yervoy 2,900 2,530 +14.6%
Zeposia 577 566 +1.9%
Show Geography breakouts
Non Us 13,828 13,199 +4.8%
Other 1,087 996 +9.1%
US 33,279 34,105 -2.4%
Show — breakouts
Revenue 48,194 48,300 -0.2%
Show Alliances and Collaboration Companies [Axis] breakouts
Ono 510 491 +3.9%
Ono · Collaborative Arrangement 331 333 -0.6%
Pfizer 14,443 13,333 +8.3%
Pfizer · Collaborative Arrangement 115 146 -21.2%
Show Type Of Arrangement breakouts
Collaborative Arrangement 15,035 14,066 +6.9%
Cost of Revenue (FY) — — —
Show — breakouts
Cost of Revenue 13,936 13,968 -0.2%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement 6,980 6,419 +8.7%
Show Type Of Arrangement breakouts
Collaborative Arrangement 7,181 6,597 +8.9%
Selling, General & Administrative (FY) — — —
Show — breakouts
Selling, General & Administrative 7,267 8,414 -13.6%
Show Type Of Arrangement breakouts
Collaborative Arrangement 267 295 -9.5%
Research & Development (FY) — — —
Show — breakouts
Research & Development 9,951 11,159 -10.8%
Show Alliances and Collaboration Companies [Axis] breakouts
Janssen · Collaborative Arrangement 277 274 +1.1%
Show Nature Of Expense breakouts
Drug Development 4,550 4,495 +1.2%
Other 4,060 5,142 -21.0%
Other Research 1,341 1,522 -11.9%
Acquired I P R D (FY) — — —
Show — breakouts
Acquired I P R D 3,721 13,373 -72.2%
Show Type Of Arrangement breakouts
Collaborative Arrangement 3,721 13,373 -72.2%
Amortizationof Acquired Intangible Assets (FY) — — —
Show — breakouts
Amortizationof Acquired Intangible Assets 3,317 8,872 -62.6%
Other Non-Operating Income (Expense) (FY) — — —
Show — breakouts
Other Non-Operating Income (Expense) 674 893 -24.5%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement -42 -42 0.0%
Show Type Of Arrangement breakouts
Collaborative Arrangement -23 -137 +83.2%
Total Costs & Expenses (FY) — — —
Show — breakouts
Total Costs & Expenses 38,866 56,679 -31.4%
Income Before Taxes (FY) — — —
Show — breakouts
Income Before Taxes 9,328 -8,379 +211.3%
Income Tax Expense (Benefit) (FY) — — —
Show — breakouts
Income Tax Expense (Benefit) 2,272 554 +310.1%
Net Income (FY) — — —
Show Equity Components breakouts
Noncontrolling Interest 2 15 -86.7%
Retained Earnings 7,054 -8,948 +178.8%
Show — breakouts
Net Income 7,055 -8,933 +179.0%
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest (FY) — — —
Show — breakouts
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 2 15 -86.7%
Net Income (FY) — — —
Show — breakouts
Net Income 7,054 -8,948 +178.8%
EPS (Basic) (FY) — — —
Show — breakouts
EPS (Basic) 3.47 -4.41 +178.7%
EPS (Diluted) (FY) — — —
Show — breakouts
EPS (Diluted) 3.46 -4.41 +178.5%
Interest Expense (FY) — — —
Show — breakouts
Interest Expense 1,891 1,947 -2.9%
Interest Income (FY) — — —
Show — breakouts
Interest Income -586 -478 -22.6%
Comprehensive Income (FY) — — —
Show — breakouts
Comprehensive Income 6,767 -8,640 +178.3%
Wtd Avg Shares (Basic) (FY) — — —
Show — breakouts
Wtd Avg Shares (Basic) 2,034 2,027 +0.3%
Wtd Avg Shares (Diluted) (FY) — — —
Show — breakouts
Wtd Avg Shares (Diluted) 2,039 2,027 +0.6%
Marketing And Advertising Expense (FY) — — —
Show — breakouts
Marketing And Advertising Expense 1.3 1.5 -13.3%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (FY) — — —
Show — breakouts
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax -267 409 -165.3%
Income Loss From Equity Method Investments (FY) — — —
Show — breakouts
Income Loss From Equity Method Investments -47 -44 -6.8%
Gain Loss On Investments (FY) — — —
Show — breakouts
Gain Loss On Investments -280 -16 -1650.0%
Restructuring Settlement And Impairment Provisions (FY) — — —
Show — breakouts
Restructuring Settlement And Impairment Provisions 161 103 +56.3%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents (Q) — — —
Show — breakouts
Cash & Cash Equivalents 10,209 10,346 -1.3%
Available For Sale Securities Debt Securities Current (Q) — — —
Show — breakouts
Available For Sale Securities Debt Securities Current 464 513 -9.6%
Receivables Net Current (Q) — — —
Show — breakouts
Receivables Net Current 11,414 10,747 +6.2%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement 176 189 -6.9%
Show Type Of Arrangement breakouts
Collaborative Arrangement 198 221 -10.4%
Inventory (Q) — — —
Show — breakouts
Inventory 2,690 2,557 +5.2%
Other Assets Current (Q) — — —
Show — breakouts
Other Assets Current 4,613 5,617 -17.9%
Total Current Assets (Q) — — —
Show — breakouts
Total Current Assets 29,390 29,780 -1.3%
Accounts Receivable (Q) — — —
Show — breakouts
Accounts Receivable 9,592 9,012 +6.4%
Non-Current Assets
Property, Plant & Equipment (Q) — — —
Show Geography breakouts
Non Us 2,612 2,322 +12.5%
US 4,931 4,814 +2.4%
Show — breakouts
Property, Plant & Equipment 7,543 7,136 +5.7%
Goodwill (Q) — — —
Show — breakouts
Goodwill 21,754 21,719 +0.2%
Deferred Tax Assets (Q) — — —
Show — breakouts
Deferred Tax Assets 5,378 4,236 +27.0%
Available For Sale Securities Debt Securities Noncurrent (Q) — — —
Show — breakouts
Available For Sale Securities Debt Securities Noncurrent 396 320 +23.8%
Other Non-Current Assets (Q) — — —
Show — breakouts
Other Non-Current Assets 6,474 6,105 +6.0%
Total Assets (Q) — — —
Show — breakouts
Total Assets 90,038 92,603 -2.8%
Operating Lease Right-of-Use Assets (Q) — — —
Show — breakouts
Operating Lease Right-of-Use Assets 1,582 1,224 +29.2%
Show Lease Contractual Term breakouts
Commencement of San Diego Lease 370 — —
Other Assets
Intangible Assets Net Excluding Goodwill (Q) — — —
Show — breakouts
Intangible Assets Net Excluding Goodwill 19,103 23,307 -18.0%
Show Finite Lived Intangible Assets By Major Class breakouts
Computer Software Intangible Asset 389 400 -2.8%
Licensing Agreements 1,375 1,705 -19.4%
Technology Based Intangible Assets 9,739 13,217 -26.3%
Show Indefinite Lived Intangible Assets By Major Class breakouts
In Process Research And Development 7,600 7,985 -4.8%
Current Liabilities
Debt Current (Q) — — —
Show — breakouts
Debt Current 2,261 2,046 +10.5%
Accounts Payable (Q) — — —
Show — breakouts
Accounts Payable 3,575 3,602 -0.7%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement 1,599 1,463 +9.3%
Show Type Of Arrangement breakouts
Collaborative Arrangement 1,684 1,578 +6.7%
Other Liabilities Current (Q) — — —
Show — breakouts
Other Liabilities Current 17,581 18,126 -3.0%
Total Current Liabilities (Q) — — —
Show — breakouts
Total Current Liabilities 23,417 23,774 -1.5%
Current Portion of Long-Term Debt (Q) — — —
Show — breakouts
Current Portion of Long-Term Debt 1,977 1,828 +8.2%
Non-Current Liabilities
Deferred Tax Liabilities (Q) — — —
Show — breakouts
Deferred Tax Liabilities 222 369 -39.8%
Long-Term Debt (Q) — — —
Show — breakouts
Long-Term Debt 42,850 47,603 -10.0%
Other Non-Current Liabilities (Q) — — —
Show — breakouts
Other Non-Current Liabilities 5,043 4,469 +12.8%
Total Liabilities (Q) — — —
Show — breakouts
Total Liabilities 71,533 76,215 -6.1%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
3.200% To 6.875% For Notes Due 2026 To 2097 8,712 — —
Show — breakouts
Long-Term Debt 44,827 49,431 -9.3%
Operating Lease Liabilities (Q) — — —
Show — breakouts
Operating Lease Liabilities 1,826 1,370 +33.3%
Accrued Income Taxes Noncurrent (Q) — — —
Show — breakouts
Accrued Income Taxes Noncurrent 1,407 1,491 -5.6%
Stockholders' Equity
Common Stock Value Outstanding (Q) — — —
Show — breakouts
Common Stock Value Outstanding 292 292 0.0%
Additional Paid-In Capital (Q) — — —
Show — breakouts
Additional Paid-In Capital 46,387 46,024 +0.8%
Accumulated Other Comprehensive Income (Q) — — —
Show — breakouts
Accumulated Other Comprehensive Income -1,524 -1,238 -23.1%
Retained Earnings (Q) — — —
Show — breakouts
Retained Earnings 16,896 14,912 +13.3%
Treasury Stock Common Value (Q) — — —
Show — breakouts
Treasury Stock Common Value -43,579 -43,655 +0.2%
Total Stockholders' Equity (Q) — — —
Show — breakouts
Total Stockholders' Equity 18,473 16,335 +13.1%
Minority Interest (Q) — — —
Show — breakouts
Minority Interest 33 53 -37.7%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest (Q) — — —
Show Equity Components breakouts
Accumulated Other Comprehensive Income -1,524 -1,238 -23.1%
Additional Paid In Capital 46,387 46,024 +0.8%
Common Stock 292 292 0.0%
Noncontrolling Interest 33 53 -37.7%
Retained Earnings 16,896 14,912 +13.3%
Treasury Stock Common -43,579 -43,655 +0.2%
Show — breakouts
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 18,506 16,388 +12.9%
Total Liabilities & Equity (Q) — — —
Show — breakouts
Total Liabilities & Equity 90,038 92,603 -2.8%
Preferred Stock Shares Outstanding (Q) — — —
Show — breakouts
Preferred Stock Shares Outstanding 2,510 2,868 -12.5%
Preferred Stock Shares Issued (Q) — — —
Show — breakouts
Preferred Stock Shares Issued 2,510 2,868 -12.5%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization (FY) — — —
Show — breakouts
Depreciation & Amortization 4,011 9,600 -58.2%
Deferred Income Taxes (FY) — — —
Show — breakouts
Deferred Income Taxes -965 -2,089 +53.8%
Stock-Based Compensation (FY) — — —
Show — breakouts
Stock-Based Compensation 553 507 +9.1%
Impairment Of Long Lived Assets To Be Disposed Of (FY) — — —
Show — breakouts
Impairment Of Long Lived Assets To Be Disposed Of 1,098 2,963 -62.9%
Divestiture Gains And Royalties (FY) — — —
Show — breakouts
Divestiture Gains And Royalties -1,165 -1,119 -4.1%
Equity Method Investment Realized Gain Loss On Disposal (FY) — — —
Show — breakouts
Equity Method Investment Realized Gain Loss On Disposal -280 -16 -1650.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 (FY) — — —
Show — breakouts
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 351 — —
Show Contingent Consideration By Type breakouts
Contingent value rights 351 — —
Other Non-Cash Items (FY) — — —
Show — breakouts
Other Non-Cash Items 232 94 +146.8%
Increase Decrease In Receivables (FY) — — —
Show — breakouts
Increase Decrease In Receivables -295 264 -211.7%
Change in Inventory (FY) — — —
Show — breakouts
Change in Inventory -184 -486 +62.1%
Change in Accounts Payable (FY) — — —
Show — breakouts
Change in Accounts Payable -2 184 -101.1%
Increase Decrease In Other Accrued Liabilities (FY) — — —
Show — breakouts
Increase Decrease In Other Accrued Liabilities -441 1,484 -129.7%
Increase Decrease In Accrued Income Taxes Payable (FY) — — —
Show — breakouts
Increase Decrease In Accrued Income Taxes Payable -4 -1,260 +99.7%
Increase Decrease In Other Operating Capital Net (FY) — — —
Show — breakouts
Increase Decrease In Other Operating Capital Net 471 624 -24.5%
Net Cash from Operations (FY) — — —
Show — breakouts
Net Cash from Operations 14,156 15,190 -6.8%
Investing Activities
Proceeds From Sale And Maturity Of Available For Sale Securities (FY) — — —
Show — breakouts
Proceeds From Sale And Maturity Of Available For Sale Securities 1,975 1,122 +76.0%
Payments To Acquire Marketable Securities (FY) — — —
Show — breakouts
Payments To Acquire Marketable Securities -2,000 -769 -160.1%
Proceeds From Sale Of Equity Securities Fv Ni (FY) — — —
Show — breakouts
Proceeds From Sale Of Equity Securities Fv Ni 77 265 -70.9%
Capital Expenditures (FY) — — —
Show — breakouts
Capital Expenditures -1,311 -1,248 -5.0%
Divestiture And Other Proceeds (FY) — — —
Show — breakouts
Divestiture And Other Proceeds 1,071 1,099 -2.5%
Payments To Acquire Businesses Net Of Cash Acquired (FY) — — —
Show — breakouts
Payments To Acquire Businesses Net Of Cash Acquired -3,944 -21,821 +81.9%
Net Cash from Investing (FY) — — —
Show — breakouts
Net Cash from Investing -4,132 -21,352 +80.6%
Financing Activities
Proceeds From Other Short Term Debt (FY) — — —
Show — breakouts
Proceeds From Other Short Term Debt 25 99 -74.7%
Proceeds From Issuance Of Long Term Debt (FY) — — —
Show — breakouts
Proceeds From Issuance Of Long Term Debt 5,740 12,883 -55.4%
Repayments Of Long Term Debt (FY) — — —
Show — breakouts
Repayments Of Long Term Debt -10,940 -2,873 -280.8%
Payments Of Dividends (FY) — — —
Show — breakouts
Payments Of Dividends -5,045 -4,863 -3.7%
Payments For Proceeds From Stock Option Exercises And Other Adjustments (FY) — — —
Show — breakouts
Payments For Proceeds From Stock Option Exercises And Other Adjustments -128 -106 -20.8%
Net Cash from Financing (FY) — — —
Show — breakouts
Net Cash from Financing -10,348 5,127 -301.8%
Supplemental
Income Taxes Paid (FY) — — —
Show — breakouts
Income Taxes Paid 3,264 3.9 +83592.3%
Interest Paid (FY) — — —
Show — breakouts
Interest Paid 2.1 1.8 +16.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (FY) — — —
Show — breakouts
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 195 -137 +242.3%
Net Change in Cash (FY) — — —
Show — breakouts
Net Change in Cash -129 -1,172 +89.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) — — —
Show — breakouts
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 10,218 10,347 -1.2%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key